The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA)

Neuroscience and Biobehavioral Reviews

Volumn 27, Issue 3, 2003, Pages 199-217

  Cole, Jon C ^a   Sumnall, Harry R ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Dependence; Dopamine; Drug discrimination; Ecstasy; MDMA; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; DOPAMINE; DOPAMINE RECEPTOR; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; STREET DRUG;

AGGRESSION; ANTINOCICEPTION; ANXIETY; BEHAVIORAL SCIENCE; BODY TEMPERATURE; CARDIOTOXICITY; CHICK EMBRYO; DEPRESSOR RESPONSE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG CLASSIFICATION; DRUG DISCRIMINATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG OXIDATION; DRUG POTENCY; DRUG SELF ADMINISTRATION; DRUG SURVEILLANCE PROGRAM; HUMAN; HYPERTHERMIA; HYPOTHERMIA; INSTRUMENTAL CONDITIONING; LIVER TOXICITY; LOCOMOTION; LOW DRUG DOSE; NEUROPHARMACOLOGY; NEUROTOXICITY; NEUROTOXICOLOGY; NONHUMAN; PLACE PREFERENCE; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REINFORCEMENT; REVIEW; REWARD; SENSORIMOTOR FUNCTION; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM; SEX DIFFERENCE; SOCIAL BEHAVIOR; SPECIES COMPARISON; SPECIES DIFFERENCE; STRAIN DIFFERENCE; THERMOREGULATION; TOXICOKINETICS; TRANQUILIZING ACTIVITY;

EID: 0037604799     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7634(03)00031-9     Document Type: Review

References (313)

1. The Merck index: an Encyclopaedia of chemicals, drugs, and biologicals, Merck and Co. 2002.
2. Acquas E., Marrocu P., Pisanu A., Cadoni C., Zernig G., Saria A., Di Chiara G. Intravenous administration of ecstasy (3,4-methylenedioxymethamphetamine) enhances cortical and striatal acetylcholine release in vivo. Eur J Pharmacol. 418:2001;207-211.
3. Adamec R.E., Sayin U., Brown A. The effects of corticotrophin releasing factor (CRF) and handling stress behavior in the elevated plus-maze test of anxiety. J Psychopharmacol. 5:1991;175-186.
4. Agren G., Olsson C., Uvnas-Moberg K., Lundeburg T. Olfactory cues from an oxytocin-injected male rat can reduce energy loss in its cagemates. NeuroReport. 8:1997;2551-2555.
5. Aguirre N., Barrionuevo M., Lasheras B., Del Rio J. The role of dopaminergic systems in the perinatal sensitivity to 3,4-methylenedioxymethamphetamine-induced neurotoxicity in rats. J Pharmacol Exp Ther. 286:1998;1159-1165.
6. Akram G., Galt M. A profile of harm reduction practices and co-use of illicit drugs amongst users of dance-drugs. Drugs: Educ, Prev Policy. 6:1999;212-225.
7. Al-Sahli W., Ahmad H., Kheradmand K., Connolly C., Docherty J.R. Effects of methylenedioxymethamphetamine on noradreneline-evoked contractions of rat right ventricle and small mesenteric artery. Eur J Pharmacol. 422:2001;167-174.
8. Appel J.B., West W.B., Rolandi W.G., Alici T., Pechersky K. Increasing the selectivity of drug discrimination procedures. Pharmacol Biochem Behav. 64:1999;353-358.
9. Aulakh C.S., Hill J.L., Wozniak K.M., Murphy D.L. Fenfluramine induced suppression of food intake and locomotor activity is differentially altered by the selective monoamine oxidase inhibitor clorgyline. Psychopharmacology. 95:1988;313-317.
10. Axt K.J., Mamounas L.A., Molliver M.E. Amphetamine and its analogs: psychopharmacology, toxicology and abuse. Amphetamine and its analogs: psychopharmacology, toxicology and abuse. 1994;. p. 315-67.
11. Baggott M., Heifets B., Jones R.T., Mendelson J., Sferios E., Zehnder J. Chemical analysis of Ecstasy pills. J Am Med Assoc. 284:2000;2190-2191.
12. Bai F., Lau S.S., Monks T.J. Glutathione and N -acetylcysteine conjugates of alpha-methyldopamine produce serotonergic neurotoxicity: possible role in methylenedioxyamphetamine-mediated neurotoxicity. Chem Res Toxicol. 12:1999;1150-1157.
13. Baker L.E., Broadbent J., Micheal E.K., Matthews P.K., Metosh C.A., Saunders R.B., West W.B., Appel J.B. Assessment of the discriminative stimulus effects of the optical isomers of ecstasy (3,4-methylenedioxymethamphetamine; MDMA). Behav Pharmacol. 6:1995;263-275.
14. Baker L.E., Makhay M.M. Effects of (+)-fenfluramine on 3,4-methylenedioxymethamphetamine (MDMA) discrimination in rats. Pharmacol Biochem Behav. 53:1996;455-461.
15. Baker L.E., Taylor M.M. Assessment of the MDA and MDMA optical isomers in a stimulant-hallucinogen discrimination. Pharmacol Biochem Behav. 57:1997;737-748.
16. Baker L.E., Virden T.B., Miller M.E., Sullivan C.L. Time course analysis of the discriminative stimulus effects of the optical isomers of 3,4-methylenedioxymethamphetamine (MDMA). Pharmacol Biochem Behav. 58:1997;505-516.
17. Baldwin J.D. The behavior of squirrel monkeys (saimiri) in natural environments. 1996.
18. Bamber C., Sheerin K., Tysome J., Fitzsimons J.T. Failure of subcutaneous injection of 3,4-methylenedioxymethamphetamine (MDMA) to stimulate drinking in rat. J Physiol. 506:1998;143.
19. Bankson M.B., Cunningham K.A. 3,4-Methylenedioxymethamphetamine as a unique model of serotonin receptor function and serotonin-dopamine interactions. J Pharmacol Exp Ther. 297:2001;846-852.
20. 2 receptors. Neuropsychopharmacology. 26:2002;40-52.
21. Bardo M.T., Bevins R.A. Conditioned place preference: what does it add to our preclinical understanding of drug reward? Psychopharmacology. 153:2000;31-43.
22. Battaglia G., De Souza E.B. Pharmacological profile of amphetamine derivatives at various brain recognition sites: selective effects on serotonergic systems. NIDA Res Monograph. 94:1989;240-258.
23. Battaglia G., Zaczek R., De Souza E.B. MDMA effects in brain: pharmacologic profile and evidence of neurotoxicity from neurochemical and autoradiographic studies. 1990;. p. 171-99.
24. Bauer L.O., Gross J.B., Meyer R.E., Greenblatt D.J. Chronic alcohol abuse and the acute sedative and neurophysiologic effects of midazolam. Psychopharmacology. 133:1997;293-299.
25. Bean P., Stratford N., White C., Goodman M., Maylon T., Charles V., O'Hagan C., Woolvert G. Release drugs and dance survey: an insight into the culture. 1997;1-32.
26. Beardsley P.M., Balster R.L., Harris L.S. Self-administration of methylenedioxymethamphetamine (MDMA) by rhesus monkeys. Drug Alcohol Depend. 18:1986;149-157.
27. Bengel D., Murphy D.L., Andrews A.M., Wichems C.H., Feltner D., Heils A., Mussner R., Westphal H., Lesch K.P. Altered brain serotonin homeostasis and locomotor insensitivity to 3,4-methylenedioxymethamphetamine (ecstasy) in serotonin transporter-deficient mice. Mol Pharmacol. 53:1998;649-655.
28. Bhattacharya S.K., Battacharya A., Ghosal S. Anxiogenic activity of methylenedioxymethamphetamine (ecstasy): an experimental study. Biogenic Amines. 14:1998;217-237.
29. Bilsky E.J., Hubbell C.L., Delconte J.D., Reid L.D. MDMA produces a conditioned place preference and elicits ejaculation in male rats: a modulatory role for the endogenous opioids. Pharmacol Biochem Behav. 40:1991;443-447.
30. Bilsky E.J., Hui Y., Hubbell C.L., Reid L.D. Methylenedioxymethamphetamine's capacity to establish place preferences and modify intake of an alcoholic beverage. Pharmacol Biochem Behav. 37:1990;633-638.
31. Bilsky E.J., Montegut M.J., Nichols M.L., Reid L.D. CGS 10746B, a novel dopamine release inhibitor, blocks the establishment of cocaine and MDMA conditioned place preferences. Pharmacol Biochem Behav. 59:1998;215-220.
32. Bilsky E.J., Reid L.D. MDL 72222, a serotonin 5-HT3 receptor antagonist, blocks MDMA's ability to establish a conditioned place preference. Pharmacol Biochem Behav. 39:1991;509-512.
33. Boobis A.R., Seddon C.E., Davies D.S. Bufuralol 1-hydroxylase activity of the rat. Strain differences and effects of inhibitors. Biochem Pharmacol. 35:1986;2961-2965.
34. Briley M., Chopin P., Moret C. The role of serotonin in anxiety: behavioural approaches. 1991;. p. 56-73.
35. Broadbent J., Appel J.B., Michael E.K., Ricker J.H. Discriminative stimulus effects of the optical isomers of 3,4-methylenedioxyamphetamine (MDA). Behav Pharmacol. 3:1992;443-454.
36. Broening H.W., Bacon L., Slikker JW. Age modulates the long-term but not the acute effects of the serotonergic neurotoxicant 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther. 271:1994;286-293.
37. Broening H.W., Morford L.L., Inman-Wood S.L., Fukumura M., Vorhees C.V. 3,4-Methylenedioxymethamphetamine (ecstasy)-induced learning and memory impairments depend on the age of exposure during early development. J Neurosci. 21:2001;3228-32235.
38. Bronson M.E., Jiang W., Clark C.R., DeRuiter J. Effects of designer drugs on the chicken embryo and 1-day-old chicken. Brain Res Bull. 34:1994;143-150.
39. Burns N., Olverman H.J., Kelly P.A., Williams B.C. Effects of ecstasy on aldosterone secretion in the rat In vivo and in vitro. Endocrine Res. 22:1996;601-606.
40. Callahan P.M., Appel J.B. Differences in the stimulus properties of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine in animals trained to discriminate hallucinogens from saline. J Pharmacol Exp Ther. 246:1988;866-870.
41. Callaway C.W., Geyer M.A. Stimulant effects of 3,4-methylenedioxymethamphetamine in the nucleus accumbens of rat. Eur J Pharmacol. 214:1992;45-51.
42. 1B agonist. J Pharmacol Exp Ther. 263:1992;318-326.
43. Callaway C.W., Johnson M.P., Gold L.H., Nichols D.E., Geyer M.A. Amphetamine derivatives induce locomotor hyperactivity by acting as indirect serotonin agonists. Psychopharmacology. 104:1991;293-301.
44. Callaway C.W., Wing L.L., Geyer M.A. Serotonin release contributes to the locomotor stimulant effects of 3,4-methylenedioxymethamphetamine in rats. J Pharmacol Exp Ther. 254:1990;456-464.
45. Capurro A., Reyes-Paroda M., Olazabal D., Perrone R., Silveira R., Macadar O. Aggressive behaviour and jamming avoidance response in weakly electric fish Gymnotus carapo: effects of methylenedioxymethamphetamine (MDMA). Comp Biochem Physiol. 118A:1997;831-840.
46. 3 receptor antagonists block morphine and nicotine but not amphetamine induced reward. Psychopharmacology. 97:1989;175-178.
47. Carvalho M., Carvalho F., Bastos M.L. Is hyperthermia the triggering factor for the hepatotoxicity induced by 3,4-methylenedioxymethamphetamine (ecstasy)? An in vitro study using freshly isolated mouse hepatocytes. Arch Toxicol. 74:2001;789-793.
48. Che S., Johnson M., Hanson G.R., Gibb J.W. Body temperature effect on methylenedioxymethamphetamine-induced acute decrease in tryptophan hydroxylase activity. Eur J Pharmacol. 293:1995;447-453.
49. Cho A.K., Hiramatsu M., Distenfamo E.W., Chang A.S., Jenden D.J. Stereochemical differences in the metabolism of 3,4-methylenedioxymethamphetamine in vivo and in vitro: a pharmacokinetic analysis. Drug Metab Dispos. 18:1990;686-691.
50. Cohen C., Perrault G., Sanger D.J. Assessment of the antidepressant-like effects of L-type voltage-dependent channel modulators. Behav Pharmacol. 8:1997;629-638.
51. Colado M.I., O'Shea E., Granados R., Esteban B., Martin A.B., Green A.R. Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of dark agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) administration. Br J Pharmacol. 126:1999;911-924.
52. Colado M.I., O'Shea E., Granados R., Misra A., Murray T.K., Green A.R. A study of the neurotoxic effect of MDMA (ecstasy) on 5-HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy. Br J Pharmacol. 121:1997;827-833.
53. Colado M.I., Williams J.L., Green A.R. The hyperthermic and neurotoxic effects of ecstasy (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the dark agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol. 115:1995;1281-1289.
54. Cole J.C., Bailey M., Sumnall H.R., Wagstaff G.F., King L.A. The content of ecstasy tablets: implications for the study of their long-term effects. Addiction. 97:2002;1531-1536.
55. Cole J.C., Sumnall H.R. Altered States: the clinical effects of ecstasy. Pharmacol Ther. 98:2002;35-58.
56. Collins D.M., Myers R.D. Buspirone attenuates volitional alcohol intake in the chronically drinking monkey. Alcohol. 4:1987;49-56.
57. Connor T.J., Connelly D.B., Kelly J.P., Methylenedioxymethamphetamine M.D.M.A. Ecstasy) suppresses antigen-specific IgG2a and IFN-Gamma production. Immunol Lett. 78:2001;67-73.
58. Connor T.J., Dennedy M.C., Harkin A., Kelly J.P. Methylenedioxymethampetamine-induced suppression of interleukin-1beta and tumour necrosis factor-alpha is not mediated by serotonin. Eur J Pharmacol. 148:2001;147-152.
59. Connor T.J., Kelly J.P., Leonard B.E. An assessment of the acute effects of the serotonin releasers methylenedioxymethamphetamine, methylenedioxyamphetamine and fenfluramine on immunity in rats. Immunopharmacology. 46:2000;223-235.
60. Connor T.J., Kelly J.P., McGee M., Leonard B.E. Methylenedioxymethamphetamine (MDMA; Ecstasy) suppresses IL-1b and TNF-a secretion following an in vivo lipopolysaccharide challenge. Life Sci. 67:2000;1601-1612.
61. Connor T.J., McNamara M.G., Finn D., Currid A., O'Malley M., Redmond A.M., Kelly J.P., Leonard B.E. Acute 3,4-methylenedioxymethamphetamine (MDMA) administration produces a rapid and sustained suppression of immune function in the rat. Immunopharmacology. 38:1998;253-260.
62. Connor T.J., McNamara M.G., Kelly J.P., Leonard B.E. 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) administration produces dose-dependent neurochemical, endocrine and immune changes in the rat, Human Psychopharmacology Clinical and Experimental. 14:1999;95-104.
63. 2+-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylenedioxymethamphetamine, p -chloroamphetamine and (+)-fenfluramine. Br J Pharmacol. 121:1997;1735-1743.
64. Crisp T., Stafinsky J.L., Boja J.W., Schechter M.D. The antinociceptive effects of 3,4-methylenedioxymethamphetamine (MDMA) in the rat. Pharmacol Biochem Behav. 34:1989;497-501.
65. Dafters R.I. Effect of ambient temperature on hyperthermia and hyperkinesis induced by 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) in rats. Psychopharmacology. 114:1994;505-508.
66. Dafters R.I. Hyperthermia following MDMA administration in rats: effects of ambient temperature, water consumption, and chronic dosing. Physiol Behav. 58:1995;877-882.
67. Dafters R.I., Lynch E. Persistent loss of thermoregulation in the rat induced by 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) but not by fenfluramine. Psychopharmacology. 138:1998;207-212.
68. 2A receptor response. Pharmacol Biochem Behav. 55:1996;387-396.
69. Davidson C., Gow A.J., Lee T.L.H., Ellinwood E.H. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Rev. 36:2001;1-22.
70. Davis W.M., Borne R.F. Pharmacologic investigation of compounds related to 3,4-methylenedioxyamphetamine (MDA). Subst Alcohol Actions Misuse. 5:1984;105-110.
71. Day J., Fibiger H.C. Dopaminergic regulation of cortical acetylcholine release. Synapse. 12:1992;281-286.
72. De La Torre R., Farrn M., Ortuco J., Mas M., Brenneisen R., Roset P.N., Segura J., Cami J. Non-linear pharmacokinetics of MDMA (Ecstasy) in humans. Br J Clin Pharmacol. 49:2000;104-109.
73. De La Torre R., Farrn M., Roset P.N., Hernondez L., Mas M., Ortuco J., Menoyo E., Pizarro N., Segura J., Cami J. Pharmacology of MDMA in humans. Ann NY Acad Sci. 914:2000;223-229.
74. De Souza I., Kelly J.P., Harkin A.J., Leonard B.E. An appraisal of the pharmacological and toxicological effects of a single oral administration of 3,4-methylenedioxymethamphetamine (MDMA) in the rat. Pharmacol Toxicol. 80:1997;207-210.
75. Dekeyne A., Denorme B., Monneyron S., Millan M.J. Citalopram reduces social interaction in rats by activation of serotonin (5-HT)(2C) receptors. Neuropharmacology. 39:2000;1114-1117.
76. Dickinson S.L., Tulloch I.F., Gadie B. Effects of idazoxan on 5-hydroxytryptamine-mediated behaviour in the mouse and rat. J Psychopharmacol. 5:1991;187-195.
77. Downing J. The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs. 18:1986;335-340.
78. Essman W.B., Cooper B.E. Serotonin and early development. 1978;. p. 69-152.
79. Esteban B., O'Shea E., Camarero J., Sanchez V., Green A.R., Colado M.I. 3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose. Psychopharmacology. 154:2001;251-260.
80. Evans S.M., Johanson C.E. Discriminativce stimulus properties of (±)-3,4-methylenedioxymethamphetamine and (±)-3,4-methylenedioxyamphetamine in pigeons. Drug Alcohol Depend. 18:1986;159-164.
81. Evans S.M., Zachny J.P., Johanson C.E. Three-choice discrimination among (+)-amphetamine, fenfluramine and saline in pigeons. Pharmacol Biochem Behav. 35:1990;971-980.
82. Fantegrossi W.E., Ullrich T., Rice K.C., Woods J.H., Winger G. Methylenedioxymethamphetamine (MDMA ecstasy) and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement. Psychopharmacology. 161:2002;356-364.
83. Farfel G.M., Seiden L.S. Role of hypothermia in the mechanism of protection against serotonergic toxicity. I. Experiments using 3,4-methylenedioxymethamphetamine, dizocilpine, CGS 19755 and NBQX. J Pharmacol Exp Ther. 272:1995;860-867.
84. Farfel G.M., Vosmer G.L., Seiden L.S. The N -methyl-D-aspartate antagonist MK-801 protects against serotonin depletions induced by methamphetamine, 3,4-methylenedioxymethamphetamine and p -chloroamphetamine. Brain Res. 595:1992;121-127.
85. File S.E. Animal models for predicting clinical efficacy of anxiolytic drugs: social behaviour. Neuropsychobiology. 13:1985;55-62.
86. File S.E., Baldwin H.A. Effects of b -carbolines in animal models of anxiety. Brain Res Bull. 19:1987;293-299.
87. Finch E., Sell L., Arnold D. Cerebral oedema after MDMA (ecstasy) and unrestricted water intake. Br Med J. 313:1996;690.
88. Finnegan K.T., Skratt J.J., Irwin I., Langston J.W. The N -methyl-D-aspartate (NMDA) receptor antagonist, dextrorphan, prevents the neurotoxic effects of 3,4-methylenedioxymethamphetamine (MDMA) in rats. Neurosci Lett. 105:1990;300-306.
89. Fischer H.S., Zernig G., Schatz D.S., Humpel C., Saria A. MDMA (ecstasy) enhances basal acetylcholine release in brain slices of the rat striatum. Eur J Neurosci. 12:2000;1385-1390.
90. Fisher J.F., Cho A.K. Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J Pharmacol Exp Ther. 208:1979;203-209.
91. Fitzgerald J.L., Reid J.J. Sympathomimetic actions of methylenedioxymethamphetamine in rat and rabbit isolated cardiovascular tissues. J Pharm Pharmacol. 46:1994;826-832.
92. Fitzgerald R.L., Blanke R.V., Rosecrans J.A., Glennon R.A. Stereochemistry of the metabolism of MDMA to MDA. Life Sci. 45:1989;295-301.
93. Fone K.C.F., Beckett S.R.G., Topham I.A., Swettenham J., Ball M., MAddocks L. Long-term changes in social interaction and reward following repeated MDMA administration to adolescent rats without accompanying serotonergic neurotoxicity. Psychopharmacology. 159:2002;437-444.
94. Forsling M., Fallon J.K., Shah D., Tilbrook G.S., Cowan D.A., Kicman A.T., Hutt A.J. The effect of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus. Br J Pharmacol. 135:2002;649-656.
95. Frederick D.L., Ali S.F., Slikker W., Gillam M.P., Allen R.R., Paule M.G. Behavioral and neurochemical effects of chronic methylenedioxymethamphetamine (MDMA) treatment in rhesus monkeys. Neurotoxicol Teratol. 17:1995;531-543.
96. Frederick D.L., Gillam M.P., Allen R.R., Paule M.G. Acute effects of methylenedioxymethamphetamine (MDMA) on several complex brain functions in monkeys. Pharmacol Biochem Behav. 51:1995;301-307.
97. Frederick D.L., Paule M.G. Effects of MDMA on complex brain function in laboratory animals. Neurosci Biobehav Rev. 21:1997;67-78.
98. Frith C.H., Chang L.W., Lattin D.L., Walls R.C., Hamm J., Doblin R. Toxicity of methylenedioxymethamphetamine in the dog. Fundam Appl Toxicity. 9:1987;110-119.
99. Geyer M.A., Markou A. Animal models of psychiatric disorders. 1995;787-798.
100. Ghuran A., Nolan J. Recreational drug misuse: issues for the cardiologist. Heart. 83:2000;627-633.
101. Gibson D.A. Effects of d-amphetamine on multiple schedule performance in the pigeon. Psychol Sci. 7:1967;3-4.
102. Gibson E.L., Barnfield A.M., Curzon G. Dissociation of effects of chronic diazepam treatment and withdrawal on hippocampal dialysate 5-HT and mCPP-induced anxiety in rats. Behav Pharmacol. 7:1996;185-193.
103. Gill K., Amit Z. Effects of serotonin uptake blockade on food, water and ethanol consumption. Alcohol: Clin Exp Res. 11:1987;444-449.
104. Gledhill J.A., Moore D.F., Bell D., Henry J.A. Subarachnoid haemorrhage associated with MDMA abuse. J Neurol Neurosurg Psychiatry. 56:1993;1036-1037.
105. Glennon R.A., Rosecrans J.A., Young R. The use of the discriminative stimulus paradigm for studying hallucinogenic agents - a review. Psychopharmacology. 46:1982;A7.
106. Glennon R.A., Young R. Further investigation of the discriminative stimulus properties of MDA. Pharmacol Biochem Behav. 20:1984;501-505.
107. Glennon R.A., Young R. Effect of 1-(3,4-methylenedioxymethamphetamine)-2-aminopropane and its optical isomers in PMMA-trained rats. Pharmacol Biochem Behav. 72:2002;307-311.
108. Glennon R.A., Yousif M., Patrick G. Stimulus properties of 1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDA) analogs. Pharmacol Biochem Behav. 29:1988;443-449.
109. Glennon R.A., Higgs R. Investigation of MDMA-related agents in rats trained to discriminate MDMA from saline. Pharmacol Biochem Behav. 43:1992;759-763.
110. Glennon R.A., Misenheimer B.R. Stimulus effects of N -monoethyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDE) and N -hydroxy-1-(3,4-methylenedioxyphenyl)-2-aminopropane ( N -OH MDA) in rats trained to discriminate MDMA from saline. Pharmacol Biochem Behav. 33:1989;909-912.
111. 1A serotonin agonist 8-hydroxy-2-(di- n -propylamino)tetralin. Pharmacol Biochem Behav. 66:2000;483-488.
112. Glennon R.A., Young R., Dukat M., Cheng Y. Initial characterization of PMMA as a discriminative stimulus. Pharmacol Biochem Behav. 57:1997;151-158.
113. Goad PT. Report: acute and subacute oral toxicity study of methylenedioxymethamphetamine in rats. Protocol No EMD-AT-001. Redfield, Arkansas: Intox Laboratory; 1985.
114. Gold L.H., Hubner C.B., Koob G.F. A role for the mesolimbic dopamine system in the psychostimulant actions of MDMA. Psychopharmacology. 99:1989;40-47.
115. Gold L.H., Koob G.F. Methysergide potentiates the hyperactivity produced by MDMA in rats. Pharmacol Biochem Behav. 29:1988;645-648.
116. Gold L.H., Koob G.F. MDMA produces stimulant-like conditioned locomotor activity. Psychopharmacology. 99:1989;352-356.
117. Gonzalez F.J., Meyer U.A. Molecular genetics of the debrisoquine-sparteine polymorphism. Clin Pharmacol Ther. 50:1991;233-238.
118. Goodwin A.K., Baker L.E. A three choice discrimination procedure dissociates the discriminative stimulus effects of d-amphetamine and MDMA in rats. Exp Clin Psychopharmacol. 8:2001;415-423.
119. Gordon C.J., Fogelson L. Metabolic and thermoregulatory responses of the rat maintained in acrylic or wire-screen cages: implications for pharmacological studies. Physiol Behav. 56:1994;73-79.
120. Gordon C.J., Watkinson W.P., O'Callaghan J.P., Miller D.B. Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat. Pharmacol Biochem Behav. 38:1991;339-344.
121. Gough B., Ali S.F., Slikker W., Holson R.R. Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate. Pharmacol Biochem Behav. 39:1991;619-623.
122. Gouzoulis E., von Bardeleben U., Rupp A., Kovar K.A., Hermle L. Neuroendocrine and cardiovascular effects of MDE in healthy volunteers. Neuropsychopharmacology. 8:1993;187-193.
123. Green A.R., Cross A.J., Goodwin G.M. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or ecstasy). Psychopharmacology. 119:1995;247-260.
124. Griebel G. 5-hydroxytryptamine -interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol Ther. 65:1995;319-395.
125. Griebel G., Rodgers R.J., Perrault G., Sanger D.J. Risk assessment behaviour: evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test. Pharmacol Biochem Behav. 57:1997;817-827.
126. Griffiths P., Vingoe L. The use of amphetamines, ecstasy and LSD in the European Community: a review of data on consumption patterns and current epidemiological literature. 1997.
127. Grob C.S. Deconstructing ecstasy: the politics of MDMA research, addiction. 2000.
128. Gu X.F., Azmita E.C. Integrative transporter-mediated release from cytoplasmic and vesicular 5-hydroxytryptamine stores in cultured neurons. Eur J Pharmacol. 235:1993;51-57.
129. Gudelsky G.A., Nash J.F. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J Neurochem. 66:1996;243-249.
130. 2 receptor agonists. Eur J Pharmacol. 264:1994;325-330.
131. Hall A.P. Hyponatraemia, water intoxication and ecstasy. Intensive Care Med. 23:1997;1289.
132. Handley S.L. 5-Hydroxytryptamine pathways in anxiety and its treatment. Pharmacol Ther. 66:1995;103-148.
133. Handley S.L., McBlane J.W. 5-HT drugs in animal models of anxiety. Psychopharmacology. 112:1993;13-20.
134. Hardman H.F., Haavik C.O., Seevers M.H. Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals. Toxicol Appl Pharmacol. 25:1973;299-309.
135. Harries D.P., De Silva R. Ecstasy and intracerebral haemorrhage. Scott Med J. 37:1992;150-152.
136. Harrington R.D., Woodward J.A., Hooton T.M., Horn J.R. Life threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma hydroxybutyrate. Arch Intern Med. 159:1999;2221-2224.
137. Harris D.S., Baggott M., Mendelson J.H., Mendelson J.E., Jones R.T. Subjective and hormonal effects of 3,4methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology. 162:2002;396-405.
138. Hegadoren K.M., Baker G.B., Bourin M. 3,4-Methylenedioxymethamphetamine analogues of amphetamine: defining the risks to humans. Neurosci Biobehav Rev. 23:1999;539-553.
139. Heinz A., Jones D.W. Serotonin transporters in Ecstasy users. Br J Psychiatry. 176:2000;193-194.
140. Hekmatpanah C.R., Peroutka S.J. 5-hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine-releasing effect of 3,4-methylenedioxymethamphetamine and related agents. Eur J Pharmacol. 177:1990;95-98.
141. Henderson S. Fun, frission and fashion [ecstasy, lsd, amphetamines and nightclubs, raves and parties]. Int J Drug Policy. 4:1993;122-129.
142. Henry J.A., Hill I.R. Fatal interaction between ritonavir and MDMA. Lancet. 352:1998;1751.
143. Henry J.A., Jeffreys K.J., Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine (ecstasy). Lancet. 340:1992;384-387.
144. Hiramatsu M., Kumagai Y., Unger S.E., Cho A.K. Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. J Pharmacol Exp Ther. 254:1990;521-527.
145. Hiramatsu M., Nabeshima T., Kameyama T., Maeda Y., Cho A.K. The effect of optical isomers of 3,4-methylenedioxymethamphetamine (MDMA) on stereotyped behavior in rats. Pharmacol Biochem Behav. 33:1989;343-347.
146. Horan B., Gardner E.L., Ashby C.R. Jr. Enhancement of conditioned place preference response to cocaine in rats following subchronic administration of 3,4-methylenedioxymethamphetamine (MDMA). Synapse. 35:2000;160-162.
147. House R.V., Thomas P.T., Bhargava H.N. Selective modulation of immune function resulting from in vitro exposure to methylenedioxymethamphetamine (Ecstasy). Toxicology. 96:1995;59-69.
148. Hubner C.B., Bird M., Rassnick S., Kornetsky C. The threshold lowering effects of MDMA (ecstasy) on brain-stimulation reward. Psychopharmacology. 95:1988;49-51.
149. Imperato A., Obinu M.C., Gessa G.L. Effects of cocaine and amphetamine on acetylcholine release in the hippocampus and caudate nucleus. Eur J Pharmacol. 238:1993;377-381.
150. Iravani M.M., Asari D., Patel J., Wieczorek W.J., Kruk Z.L. Direct effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin or dopamine release and uptake in the caudate putamen, nucleus accumbens, substantia nigra pars reticulata, and the dorsal raphn nucleus slices. Synapse. 36:2000;275-285.
151. 3H]-dopamine release from superfused rat brain slices. Eur J Pharmacol. 132:1986;269-276.
152. Johnson M.P., Huang X., Nichols D.E. Serotonin neurotoxicity in rats after combined treatment with a dopaminergic agent followed by a nonneurotoxic 3,4-methylenedioxymethamphetamine (MDMA) analogue. Pharmacol Biochem Behav. 40:1991;915-922.
153. Johnson M.P., Nichols D.E. Combined administration of a non-neurotoxic 3,4-methylenedioxymethamphetamine analogue with amphetamine produces serotonin neurotoxicity in rats. Neuropharmacology. 30:1991;819-822.
154. Johnston L.D., O'Malley P.M., Bachman J.G. Rise in ecstasy use among American teens begins to slow. 2002;University of Michigan News and Information Services, Ann Arbor, MI. On-line.
155. Kalivas P.W., Duffy P., White S.R. MDMA elicits behavioral and neurochemical sensitisation in rats. Neuropsychopharmacology. 18:1998;469-479.
156. Kamien J.B., Johanson C.E., Schuster C.R., Woolverton W.L. The effects of (+/-)-methylenedioxymethamphetamine and (+/-)-methylenedioxyamphetamine in monkeys trained to discriminate (+)-amphetamine from saline. Drug Alcohol Depend. 18:1986;134-147.
157. Kehne J.H., McCloskey T.C., Taylor V.L., Black C.K., Fadayel G.M., Schmidt C.J. Effects of the serotonin releasers 3,4-methylenedioxymethamphetamine (MDMA), 4-chloroamphetamine (PCA) and fenfluramine on acoustic and tactile startle reflexes in rats. J Pharmacol Exp Ther. 260:1992;78-89.
158. Kehne J.H., Padich R.A., McCloskey T.C., Taylor V.L., Schmidt C.J. 5-HT modulation of auditory and visual sensorimotor gating: I. effects of 5-HT releasers on sound and light prepulse inhibition in Wistar rats. Psychopharmacology. 124:1996;95-106.
159. Kish S.J. How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? Pharmacol Biochem Behav. 71:2002;845-855.
160. Koch S., Galloway M.P. MDMA induced dopamine release in vivo: role of endogenous serotonin. J Neural Transm. 104:1997;135-146.
161. Korte S.M. Corticosteroids in relation to fear, anxiety and psychopathology. Neurosci Biobehav Rev. 25:2001;117-142.
162. 3H]5-hydroxytryptamine from fetal and maternal brain by drugs of abuse. Brain Res Dev Brain Res. 78:1994;142-146.
163. Kreth K.P., Kovar K.A., Schwab M., Zanger U.M. Identification of the human cytochromes P450 involved in the oxidative metabolism of 'Ecstasy'-related designer drugs. Biochem Pharmacol. 59:2000;1563-1571.
164. Kronick J.B., Whelan D.T., McCallion D.J. Experimental hyperphenylalanimemia in the pregnant guinea pig: Possible phenylslnine teratogenesis and p -chlorophenylalanine embryotoxicity. Teratology. 36:1987;245-258.
165. Kuhn D.M., Geddes T.J. Molecular footprints of neurotoxic amphetamine action. Ann NY Acad Sci. 914:2000;92-103.
166. Kuikka J.T., Ahonen A.K. Lancet. 353:2002;1269.
167. Kulmala H.K., Boja J.W., Schechter M.D. Behavioral suppression following 3,4-methylenenedioxymethamphetamine. Life Sci. 41:1987;1425-1429.
168. Kumagai Y., Wickham K.A., Schmitz D.A., Cho A.K. Metabolism of methylenedioxyphenyl compounds by rabbit liver preparations: participation of different cytochrome P450 isozymes in the demethylenation reaction. Biochem Pharmacol. 42:1991;1061-1067.
169. Kutscher C.L., Yamamoto B.K. A frequency analysis of behavior components of the serotonin syndrome produced by p -chloroamphetamine. Pharmacol Biochem Behav. 11:1979;611-616.
170. Lamb R.J., Griffiths R.R. Self-injection of d,1-3,4-methylmenedioxymethamphetamine (MDMA) in the baboon. Psychopharmacology. 91:1987;268-272.
171. Lavelle A., Honner V., Docherty J.R. Investigation of the prejunctional alpha2-adrenoceptor mediated actions of MDMA in rat atrium and vas deferens. Br J Pharmacol. 128:1999;975-980.
172. Leonardi E.T.K., Azmitia E.C. MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharmacology. 10:1994;231-238.
173. LeSage M., Clark R., Poling A. MDMA and memory: the acute and chronic effects of MDMA in pigeons performing under a delayed-matching-to-sample procedure. Psychopharmacology. 110:1993;327-332.
174. LeSage M., Poling A. MDMA and d -amphetamine produce comparable effects in pigeons performing under a multiple fixed-ratio interresponse-time-greater-than- t schedule of food delivery. Pharmacol Biochem Behav. 57:1997;173-177.
175. Lester S.J., Baggott M., Welm S., Schiller N.B., Jones R.T., Foster E., Mendelson J. Cardiovascular effects of 3,4-methylenedioxymethamphetamine: a double blind, placebo-controlled trial. Ann Intern Med. 133:2000;969-973.
176. Levi G., Raiteri M. Carrier mediated release of neurotransmitters.
177. Li A.A., Marek G.J., Vosmer G., Seiden L.S. Long-term central 5-HT depletions resulting from repeated administration of MDMA enhances the effects of single administration of MDMA on schedule-controlled behavior of rats. Pharmacol Biochem Behav. 33:1989;641-648.
178. Lim H.K., Foltz R.L. In vivo and in vitro metabolism of 3,4-methylenedioxymethamphetamine in the rat: Identification of metabolites using an ion trap detector. Chem Res Toxicol. 1:1988;370-378.
179. Lin H.Q., Burden P.M., Christie M.J., Johnston G.A. The anxiogenic-like and anxiolytic-like effects of MDMA on mice in the elevated plus-maze: a comparison with amphetamine. Pharmacol Biochem Behav. 62:1999;403-408.
180. Lin H.Q., Jackson D.M., Atrens D.M., Christie M.J., McGregor I.S. Serotonergic modulation of 3,4-methylenedioxymethamphetamine (MDMA)-elicited reduction of response rate but not rewarding threshold in accumbal self-stimulation. Brain Res. 744:1997;351-357.
181. Lin L.Y., Kumagai Y., Cho A.K. Enzymatic and chemical demethylation of (methylenedioxy)amphetamine and (methylenedioxy)methamphetamine by rat brain microsomes. Chem Res Toxicol. 5:1992;401-406.
182. Lucas G., De Deurwaerdere P., Porras G., Spampinato U. Endogenous serotonin enhances the release of dopamine in the striatum only when nigro-striatal dopaminergic transmission is activated. Neuropharmacology. 39:2000;1984-1995.
183. 2 receptors. Psychopharmacology. 88:1986;525-526.
184. Malberg J.E., Sabol K.E., Seiden L.S. Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. J Pharmacol Exp Ther. 278:1996;258-267.
185. Malberg J.E., Seiden L.S. Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci. 18:1998;5086-5094.
186. Maldonado E., Navarro J.F. Effects of 3,4-methylenedioxy-methamphetamine (MDMA) on anxiety in mice tested in the light-dark box. Prog Neuro-Psychopharmacol Biol Psychiatry. 24:2000;463-472.
187. Maldonado E., Navarro J.F. Mdma (ecstasy) exhibits an anxiogenic-like activity in social encounters between male mice. Pharmacol Res. 44:2001;27-31.
188. Malpass A., White J.M., Irvine R.J., Somogyi A.A., Bochner F. Acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA) in Sprague-Dawley and Dark Agouti rats. Pharmacol Biochem Behav. 64:1999;29-34.
189. Mansbach R.S., Geyer M.A., Braff D.L. Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology. 94:1988;507.
190. Marona-Lewicka D., Nichols D.E. Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan. Eur J Pharmacol. 258:1994;1-13.
191. Marona-Lewicka D., Rhee G.S., Sprague J.E., Nichols D.E. Reinforcing effects of certain serotonin-releasing amphetamine derivatives. Pharmacol Biochem Behav. 53:1996;99-105.
192. McCann U.D., Ricaurte G.A. Caveat emptor: editors beware. Neuropsychopharmacology. 24:2001;333-334.
193. 2C/2B antagonist SB 206553 on hyperactivity induced by cocaine. Neuropsychopharmacology. 20:1999;556-564.
194. 3H-5-hydroxytryptamine. Pharmacol Biochem Behav. 38:1991;505-512.
195. McNamara M.G., Kelly J.P., Leonard B.E. The effect of acute MDMA administration on body temperature, serum corticosterone and neurotransmitter concentrations in male and female rats. Human Psychopharmacol. 10:1995;373-383.
196. Mechan A.O., Esteban B., O'Shea E., Elliot J.M., Colado M.I., Green A.R. The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) to rats. Br J Pharmacol. 135:2002;170-180.
197. Meehan S.M., Schechter M.D. LSD produces conditioned place preference in male but not female fawn hooded rats. Pharmacol Biochem Behav. 59:1998;105-108.
198. Meert T.F., Clincke G.H. 7-OHDPAT and alcohol consumption, withdrawal and discriminative stimulus properties in rats. Alcohol Alcohol. 29:1994;489-492.
199. Metzger R.R., Hanson G.R., Gibb J.W., Fleckenstein A.E. 3,4-Methylenedioxymethamphetamine-induced acute changes in dopamine transporter function. Eur J Pharmacol. 349:1998;205-210.
200. Meyer A., Mayerhofer A., Kovar K.A., Schmidt W.J. Rewarding effects of the optical isomers of 3,4-methylenedioxymethamphetamine (Ecstasy) and 3,4-methylenedioxymethamphetamine (Eve) measured by conditioned place preference in rats. Neurosci Lett. 330:2002;280-284.
201. Miczek K.A., Haney M. Psychomotor stimulant effects of d-amphetamine, MDMA and PCP: aggressive and schedule-controlled behavior in mice. Psychopharmacology. 115:1994;358-365.
202. 1A receptors. Eur J Pharmacol. 193:1991;145-152.
203. Miller R.T., Lau S.S., Monks T.J. 2,5-Bis-(glutathion-S-yl)-a-methyldopamine, a putative metabolite of (±)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations. Eur J Pharmacol. 323:1997;173-180.
204. Milroy C.M., Clark J.C., Forrest A.R. Pathology of deaths associated with ecstasy and eve misuse. J Clin Pathol. 49:1996;149-153.
205. Moore W.T., Hampton J.K. Effects of parachlorophenylalanine on pregnancy in the rat. Biol Reprod. 2:1974;280-287.
206. Morgan A.E., Horan B., Dewey S.L., Ashby C.R. Jr. Repeated administration of 3,4-methylenedioxymethamphetamine augments cocaine's action on dopamine in the nucleus accumbens: a microdialysis study. Eur J Pharmacol. 331:1997;R1-R3.
207. Morgan M.J. Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology. 152:2000;230-248.
208. Morley K.C., McGregor I.S. (±)-3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) increases social interaction in rats. Eur J Pharmacol. 408:2000;41-49.
209. Nader M.A., Hoffmann S.M., Barrett J.E. Behavioral effects of (±) 3,4-methylenedioxyamphetamine (MDA) and (±) 3,4-methylenedioxymethamphetamine (MDMA) in the pigeon: interactions with noradrenergic and serotonergic systems. Psychopharmacology. 98:1989;183-188.
210. Nagilla R., Newland M.C., Snyder J., Bronson M.E. Effect of once weekly treatment with 3,4-methylenedioxymethamphetamine on schedule-controlled behavior in rats. Eur J Pharmacol. 358:1998;1-8.
211. Naranjo C.A., Sellers E.M., Lawrin M.O. Modulation of ethanol intake by serotonin uptake inhibitors. J Clin Psychiatry. 47:1986;16-22.
212. Nash J.F. Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. Life Sci. 47:1990;2401-2408.
213. Nash J.F., Brodkin J. Microdialysis studies on 3,4-methylenedioxymethamphetamine-induced dopamine release: effect of dopamine uptake inhibitors. J Pharmacol Exp Ther. 259:1991;820-825.
214. Nash J.F., Meltzer H.Y. Neuroendocrinological effects of MDMA in the rat. 1990;. p. 225-39.
215. Nash J.F., Meltzer H.Y., Gudelsky G.A. Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther. 245:1988;873-879.
216. Navarro J.F., Maldonado E. Behavioral profile of 3,4-methylenedioxy-methamphetamine (MDMA) in agonistic encounters between male mice. Prog Neuro-Psychopharmacol Biol Psychiatry. 23:1999;327-334.
217. Navarro J.F., Maldonado E. Acute and subschronic effects of MDMA (ecstasy) on anxiety in male mice tested in the elevated plus-maze. Prog Neuro-Psychopharmacol Biol Psychiatry. 26:2002;1151-1154.
218. Nichols D.E. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs. 18:1986;305-313.
219. 3H]serotonin from rat brain synaptosomes. J Med Chem. 25:1982;530-535.
220. Nichols D.E., Oberlender R. Structure-activity relationships of MDMA and related compounds: a new class of psychoactive agents. 1990;. p. 105-31.
221. Nishisawa S., Mzengeza S., Diksic M. Acute effects of 3,4-methylenedioxymethamphetamine on brain serotonin synthesis in the dog studied by positron emission tomography. Neurochem Int. 34:1999;33-40.
222. O'Cain P.A., Hletko S.B., Ogden B.A., Varner K.J. Cardiovascular and sympathetic responses and reflex changes elicited by MDMA. Physiology. 70:2000;141-148.
223. O'Callaghan J.P., Miller D.B. Neurotoxic effects of substituted amphetamines in rats and mice: challenges to the current dogma. Handbook of neurotoxicology. 2001;Humana, New York.
224. O'Connell D., Heffron J.J. Rapid analysis of illicit drugs by mass spectrometry: results from seizures in Ireland. Analyst. 125:2000;119-121.
225. O'Loinsigh E.D., Kelly J.P., O'Boyle K.M. Co-administration of D-amphetamine alters the acute and long-term effects of 3,4-methylenedioxymethamphetamine in rats. Br J Pharmacol. 131:2000;154.
226. O'Loinsigh E.D., Kelly J.P., O'Boyle K.M. Evidence for a critical role of body temperature in the modulation of MDMA by drugs of abuse. Br J Pharmacol. 134:2001;37.
227. Oberlender R., Nichols D.E. Drug discrimination studies with MDMA and amphetamine. Psychopharmacology. 95:1988;71-76.
228. Oberlender R., Nichols D.E. (+)- N -methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine as a discriminative stimulus in studies of 3,4-methylenedioxymethamphetamine-like behavioral activity. J Pharmacol Exp Ther. 255:1990;1098-1106.
229. Olds M.E., Yuwiler A. Effects of acute and chronic fenfluramine on self-stimulation and its facilitation by amphetamine. Eur J Pharmacol. 216:1992;363-372.
230. Pacifici R., Zuccaro P., Farrn M., Pichini S., Di Carlo S., Roset P.N., Ortuco J., Segura J., De La Torre R. Immunomodulating properties of MDMA alone and in combination with alcohol: a pilot study. Life Sci. 65:1999;309-316.
231. Pacifici R., Zuccaro P., Hernondez L., Pichini S., Di Carlo S., Farrn M., Roset P.N., Ortu J., Segura J., De La Torre R. Acute effects of 3,4-methylenedioxymethamphetamine alone and in combination with ethanol on the immune system in humans. J Pharmacol Exp Ther. 296:2001;207-215.
232. 2A antagonist MDL 100,907 on disruption of sound and light prepulse inhibition produced by 5-HT agonists in Wistar rats. Psychopharmacology. 124:1996;107-116.
233. Pan H.S., Wang R.Y. MDMA: further evidence that its action in the medial prefrontal cortex is mediated by the serotonergic system. Brain Res. 539:1991;332-336.
234. Pan H.S., Wang R.Y. The action of (±)-MDMA on medial prefrontal cortical neurons is mediated through the serotonergic system. Brain Res. 543:1991;56-60.
235. Parrott A.C. Human psychopharmacology of ecstasy; A review of 15 years of empirical research. Human Psychopharmacol. 16:2001;557-577.
236. Pedersen N.P., Blessing W.W. Cutaneous vasoconstriction contributes to hyperthermia induced by 3,4-methylenedioxymethamphetamine (ecstasy) conscious rabbits. J Neurosci. 21:2001;8648-8654.
237. Picazo O., Lopez-Rubaclava C., Fernandez-Guasti A. Anxiolytic effect of the 5-HT1A compounds 8-hydroxy-2-di- n -propylamino tetralin and ipsapirone in the social interaction paradigm: evidence of a presynaptic action. Brain Res Bull. 37:1995;169-175.
238. Piercey M.F., Lum J.T., Palmer J.R. Effects of MDMA (ecstasy) on firing rates of serotonergic, dopaminergic, and noradrenergic neurons in the rat. Brain Res. 526:1990;203-206.
239. Plessinger M.A. Prenatal exposure to amphetamines. Risks and adverse outcomes in pregnancy. Obstet Gynecol Clin North Am. 25:1998;119-138.
240. Poling A., Cleary J., Jackson K., Wallace S. d-Amphetamine and phencyclidine alone and in combination: effects on fixed ratio and interresponse-time-greater-than- t responding of rats. Pharmacol Biochem Behav. 15:1981;357-361.
241. Ramsey J.D., Butcher M.A., Murphy M.F., Lee T., Johnston A., Holt D.W. A new method to monitor drugs at dance venues. Br Med J. 323:2001;603.
242. Ramsey M., Baker P., Goulden C., Sharp C., Sondhi A. Drug misuse declared in 2000. vol. 224:2001;. p. 1-104.
243. Ramsey M., Partridge B., Byron C. Drug misuse declared in 1998: key results from the British Crime Survey. Res Find. 93:1999;1-4.
244. Ratzenboeck E., Saria A., Kriechbaum N., Zernig G. Reinforcing effects of MDMA (Ecstasy) in drug-naive and cocaine-treated rats. Pharmacology. 62:2001;138-144.
245. Reed L.J., Winstock A., Cleare A.J., McGuire P. Toxic effect of MDMA on brain serotonin neurons. Lancet. 353:1999;1268-1271.
246. Reid L.D., Hubbell C.L., Tsai J., Fishkin M.D., Amendola C.A. Naltrindole, a d -opioid antagonist, blocks MDMA's ability to enhance pressing for rewarding brain stimulation. Pharmacol Biochem Behav. 53:1996;477-480.
247. Rempel N.L., Callaway C.W., Geyer M.A. Serotonin1B receptor activation mimics behavioral effects of presynaptic serotonin release. Neuropsychopharmacology. 8:1993;201-211.
248. Rezvani A.H., Garges P.L., Miller D.B., Gordon C.J. Attenuation of alcohol consumption by MDMA (ecstasy) in two strains of alcohol-preferring rats. Pharmacol Biochem Behav. 43:1992;103-110.
249. Rezvani A.H., Overstreet D.H., Janowsky D.S. Genetic serotonin deficiency and alcohol preference in the fawn hooded rats. Alcohol Alcohol. 25:1990;573-575.
250. Ricaurte G.A., McCann U.D., Szabo Z., Scheffel U. Toxicodynamics and long-term toxicity of the recreational drug, 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy). Toxicol Lett. 112-113:2000;143-146.
251. Ricaurte G.A., Yuan J., McCann U.D. (±)3,4-Methylenedioxymethamphetamine (Ecstasy)-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology. 42:2000;5-10.
252. Riley S.C., James C., Gregory D., Dingle H., Cadger M. Patterns of recreational drug use at dance events in Edinburgh, Scotland. Addiction. 96:2001;1035-1047.
253. Rochester J.A., Kirchner J.T. Ecstasy: history, neurochemistry and toxicology. J Am Board Family Pract. 12:1999;137-142.
254. Rodgers R.J., Cole J.C. The elevated plus-maze. Pharmacol Methodol Ethol. 1994;9-45.
255. Romano A.G., Harvey J.A. MDMA enhances associative and nonassociative learning in the rabbit. Pharmacol Biochem Behav. 47:1994;289-293.
256. Rosecrans J.A., Glennon R.A. The effect of MDA and MDMA (ecstasy) isomers in combination with pirenpirone on operant responding in mice. Pharmacol Biochem Behav. 28:1987;39-42.
257. Rothman R.B., Baumann M.H., Dersch C.M., Romero R.V., Rice K.C., Carroll F.I., Partilla J.S. Amphetamine-type central nervous stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse. 39:2001;32-41.
258. Rudnick G., Wall S.C. The molecular mechanism of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Nat Acad Sci. 89:1992;1817-1821.
259. Sabol K.E., Richards J.B., Layton K., Seiden L.S. Amphetamine analogs have differential effects on DRL 36-s schedule performance. Psychopharmacology. 121:1995;57-65.
260. Sabol K.E., Seiden L.S. Reserpine attenuates D-amphetamine and MDMA-induced transmitter release in vivo: a consideration of dose, core temperature and dopamine synthesis. Brain Res. 806:1998;69-78.
261. Saunders N. Ecstasy and the dance culture. 1995.
262. 1B receptor. Psychopharmacology. 141:1999;154-161.
263. Schechter M.D. Discriminative profile of MDMA. Pharmacol Biochem Behav. 24:1986;1533-1537.
264. Schechter M.D. Serotonergic-dopaminergic mediation of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). Pharmacol Biochem Behav. 31:1989;817-824.
265. Schechter M.D. Effect of serotonin depletion by p -chlorophenylalanine upon discriminative behaviours. General Pharmacol. 22:1991;889-893.
266. Schechter M.D. Drug-drug discrimination: stimulus properties of drugs of abuse upon a serotonergic-dopaminergic continuum. Pharmacol Biochem Behav. 56:1997;89-96.
267. Schechter M.D. Candyflipping: synergistic discriminative effect of LSD and MDMA. Eur J Pharmacol. 341:1998;131-134.
268. Schmidt C.J. Acute administration of methylenedioxymethamphetamine: comparison with the neurochemical effects of its N -desmethyl and N -ethyl analogs. Eur J Pharmacol. 136:1987;81-88.
269. Schmidt C.J. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther. 240:1987;1-7.
270. 2 receptor antagonists protect against the neurotoxicity of methylenedioxymethamphetamine in rats. J Pharmacol Exp Ther. 255:1990;478-483.
271. 2 receptors. Brain Res. 529:1990;85-90.
272. Schmidt C.J., Black C.K., Taylor V.L. L-dopa potentiation of the serotonergic deficits due to a single administration of 3,4-methylenedioxymethamphetamine, p -chloroamphetamine or methamphetamine to rats. Eur J Pharmacol. 203:1991;41-49.
273. 2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine. Eur J Pharmacol. 223:1992;65-74.
274. Schmidt C.J., Kehne J.H. Neurotoxicity of MDMA: neurochemical effects. Ann NY Acad Sci. 600:1990;665-682.
275. 2 receptors in schizophrenia and antipsychotic activity. Int Clin Psychopharmacol. 8:1993;25-32.
276. 2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. J Neurochem. 62:1994;1382-1389.
277. Schmidt C.J., Taylor V.L. Direct central effects of acute methylenedioxymethamphetamine on serotonergic neurons. Eur J Pharmacol. 156:1988;121-131.
278. Schmidt W.J., Mayerhofer A., Meyer A., Kovar K.A. Ecstasy counteracts catalepsy in rats, an anti-parkinsonian effect? Neurosci Lett. 330:2002;251-254.
279. Shankaran M., Gudelsky G.A. Effect of 3,4-methylenedioxymethamphetamine (MDMA) on hippocampal dopamine and serotonin. Pharmacol Biochem Behav. 61:1998;361-366.
280. Sherlock K., Wolff K., Hay A.W., Conner M. Analysis of illicit ecstasy tablets: implications for clinical management in the accident and emergency department. J Accid Emerg Med. 16:1999;194-197.
281. Skibba J.L., Powers R.H., Stadnicka A., Cullinane D.W., Almagro U.A., Kalbfleisch J.H. Oxidative stress as a precursor to the irreversible hepatocellular injury caused by hyperthermia. Int J Hyperthermia. 5:1991;749-761.
282. Slikker W., Holson R.R., Ali S.F., Kolta K.G., Paule M.G., Scallet A.C., McMillan D.E., Bailey J.R., Hong J.S., Scalzo F.M. Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate. Neurotoxicology. 10:1989;529-542.
283. Spanos L.J., Yamamoto B.K. Acute and subchronic effects of methylenedioxymethamphetamine [(±)MDMA] on locomotion and serotonin syndrome behavior in the rat. Pharmacol Biochem Behav. 32:1989;835-840.
284. Sprouse J.S., Bradberry C.W., Roth R.H., Aghajanian G.K. MDMA (3,4-methylenedioxymethamphetamine) inhibits the firing of dorsal raphe neurons in brain slices via release of serotonin. Eur J Pharmacol. 167:1989;375-383.
285. St. Omer V.E.V., Ali S.F., Holson R.R., Duhart H.M., Scalzo F.M., Slikker W. Behavioral and neurochemical effects of prenatal methylenedioxymethamphetamine (MDMA) exposure in rats. Neurotoxicol Teratol. 13:1991;13-20.
286. 3H]monoamines into synaptosomes from different regions of rat brain. Biochem Pharmacol. 36:1987;2297-2303.
287. Stellar J.R., Rice M.B. Pharmacological basis of intracranial self-stimulation reward. 1989;. p. 14-65.
288. Stone D.M., Johnson M., Hanson G.R., Gibb J.W. Acute inactivation of tryptophan hydroxylase by amphetamine analogs involves the oxidation of sulfhydryl sites. Eur J Pharmacol. 172:1989;93-97.
289. Stone D.M., Stahl D.C., Hanson G.R., Gibb J.W. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur J Pharmacol. 128:1986;41-48.
290. Strote J. Increasing MDMA use among college students: results of a national survey. J Adolesc Health. 30:2002;64-72.
291. Teitler M., Leonhardt S., Appel N.M., De Souza E.B., Glennon R.A. Receptor pharmacology of MDMA and related hallucinogens. Ann NY Acad Sci. 600:1990;626-639.
292. Thompson D.M., Moerschbaecher J.M. Differential effects of MDA and phencyclidine on complex operant behavior in monkeys. Pharmacol Biochem Behav. 21:1984;453-457.
293. Thompson D.M., Winsauer P.J., Mastropaolo J. Effects of phencyclidine, ketamine and MDMA on complex operant behavior in monkeys. Pharmacol Biochem Behav. 26:1987;401-405.
294. 2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology. 94:1988;213-216.
295. Tossmann P., Boldt S., Tensil M.D. The use of drugs within the techno party scene in European metropolitan cities. Eur Addict Res. 7:2001;2-23.
296. Tucker G.T., Lennard M.S., Ellis S.W., Woods H.F., Cho A.K., Lin L.Y., Hiratsuka A., Schmitz D.A., Chu T.Y. The demethylenation of methylenedioxymethamphetamine (ecstasy) by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol. 47:1994;1151-1156.
297. 2A/D-adrenoceptor knockout mice. Eur J Pharmacol. 457:2002;45-49.
298. Varner K.J., Delcarpio J.B., Moerschbaecher J.M. Cardiac toxicity elicited by repeated administration of 3,4-methylenedioxymethamphetamine (MDMA). NIDA Res Monograph. 179:1998;214.
299. Vollenweider F.X., Jones R.T., Baggott M.J. Caveat emptor: editors beware. Neuropsychopharmacology. 24:2001;461-463.
300. Vollenweider F.X., Remensberger S., Hell D., Geyer M.A. Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans. Psychopharmacology. 143:1999;365-372.
301. Watson I.D., Serlin M., Moncur P., Tames F. Acute hyponatraemia. Postgrad Med J. 73:1997;443-444.
302. White S.R., Duffy P., Kalivas P.W. Methylenedioxymethamphetamine depresses glutamate-evoked neuronal firing and increases extracellular levels of dopamine and serotonin in the nucleus accumbens in vivo. Neuroscience. 62:1994;41-50.
303. White S.R., Obradovic T., Imel K.M., Wheaton M.J. The effects of methylenedioxymethamphetamine (MDMA, ecstasy) on monoaminergic neurotransmission in the central nervous system. Prog Neurobiol. 49:1996;455-479.
304. Wichems C.H., Hollingsworth C.K., Bennett B.A. Release of serotonin induced by 3,4-methylenedioxymethamphetamine (MDMA) and other substituted amphetamines in cultured fetal raphe neurons: further evidence for calcium-independent mechanisms of release. Brain Res. 695:1995;10-18.
305. 2 subtype-selective agonists and antagonists. Psychopharmacology. 105:1991;513-520.
306. Winstock A., Griffiths P., Stewart D. Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend. 64:2001;9-17.
307. Wolff K., Hay A.W., Sherlock K., Conner M. Contents of ecstasy. Lancet. 346:1995;1100-1101.
308. A report from the WHO meeting on amphetamines, MDMA and other psychostimulanst. A report from the WHO meeting on amphetamines, MDMA and other psychostimulanst. 1997.
309. Yamamoto B.K., Nash J.F., Gudelsky G.A. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. J Pharmacol Exp Ther. 273:1995;1063-1070.
310. Yamamoto B.K., Spanos L.J. The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. Eur J Pharmacol. 148:1988;195-203.
311. Young L.J. The neurobiology of social recognition, approach, and avoidance. Biol Psychiatry. 51:2002;18-26.
312. Zacny J.P., Virus R.M., Woolverton W.L. Tolerance and cross-tolerance to 3,4-methlenedioxymethamphetamine (MDMA), methamphetamine and methylenedioxyamphetamine. Pharmacol Biochem Behav. 35:1990;637-642.
313. Zaczek R., Hurt S., Culp S., De Souza E.B. Characterization of brain interactions with methylenedioxyamphetamine and methylenedioxymethamphetamine. NIDA Res Monograph. 94:1989;239.